Tan WS, Tang CL, Koo WH
Correspondence: A/Prof Choong Leong Tang, tang.choong.leong@sgh.com.sg
ABSTRACT
Introduction The use of faecal immunochemical occult blood test (FIT) has been reported to decrease mortality from colorectal cancer. The Singapore Cancer Society (SCS) gives out FIT kits to encourage opportunistic screening of colorectal cancer. Any Singapore citizen or permanent resident aged ≥ 50 years is eligible to receive two FIT kits. Participants with at least one positive FIT are referred for further evaluation. We aimed to analyse the results of SCS data from the year 2008.
Methods The factors evaluated included compliance, positive test rate (PR) and positive predictive value (PPV) of FIT.
Results 20,989 participants received 41,978 kits in 2008. Compliance was 38.9%, with 8,156 participants returning at least one kit. 8% of participants tested positive, and 75% of these test-positive participants agreed to undergo further investigations. 33 participants had colorectal cancers, 45 had advanced polyps (≥ 1 cm) and 90 had polyps < 1 cm. Histologically, 114 polyps were adenomatous, 20 were hyperplastic and 1 was serrated. PPV of colorectal neoplasia for those who underwent further colonoscopy was 34%. Over half of the participants who had only one positive test had colorectal neoplasia.
Conclusion PR and PPV of FIT in our study were comparable to that in the literature. However, compliance was low and a quarter of all participants who tested positive refused further investigations. Extensive population education programmes are required to improve compliance and tackle inhibitions among the masses. It is also important to take steps to enhance the cost effectiveness of future screening programmes.
Keywords:colorectal cancer, faecal occult blood test, screening
Singapore Med J 2013; 54(4): 220-223; http://dx.doi.org/10.11622/smedj.2013077
REFERENCES
1. Seow A, Koh WP, Chia KS, et al. Trends in cancer incidence in Singapore, 1968-2002. Report No. 6. Singapore: Singapore Cancer Registry, 2004. | ||||
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-71. http://dx.doi.org/10.1056/NEJM199305133281901 | ||||
3. Hardcastle J D, C hamberlain J O, R obinson M H, e t a l. R andomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-7. http://dx.doi.org/10.1016/S0140-6736(96)03386-7 | ||||
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occultblood test. Lancet 1996; 348:1467-71. http://dx.doi.org/10.1016/S0140-6736(96)03430-7 | ||||
5. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29-32. http://dx.doi.org/10.1136/gut.50.1.29 | ||||
6. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95:1029-36. http://dx.doi.org/10.1002/bjs.6136 | ||||
7. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 1:CD001216. | ||||
8. Goodyear SJ, Leung E, Menon A, et al. The effects of population-based faecal occult blood test screening upon emergency colorectal cancer admissions in Coventry and north Warwickshire. Gut 2008; 57:218-22. http://dx.doi.org/10.1136/gut.2007.120253 | ||||
9. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146:244-55. http://dx.doi.org/10.7326/0003-4819-146-4-200702200-00003 | ||||
10. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100:2519-25. http://dx.doi.org/10.1111/j.1572-0241.2005.00231.x | ||||
11. Fu WP, Kam MH, Ling WM, et al. Screening for colorectal cancer using a quantitative immunochemical faecal occult blood test: a feasibility study in an Asian population. Tech Coloproctol 2009; 13:225-30. http://dx.doi.org/10.1007/s10151-009-0515-1 | ||||
12. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99:1462-70. http://dx.doi.org/10.1093/jnci/djm150 | ||||
13. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007; 14:132-7. http://dx.doi.org/10.1258/096914107782066220 PMid:17925085 | ||||
14. Chew MH, Suzanah N, Ho KS, et al. Colorectal cancer mass screening event utilising quantitative faecal occult blood test. Singapore Med J 2009; 50:348-53. | ||||
15. Chapple A, Ziebland S, Hewitson P, McPherson A. What affects the uptake of screening for bowel cancer using a faecal occult blood test (FOBt): a qualitative study. Soc Sci Med 2008; 66:2425-35. http://dx.doi.org/10.1016/j.socscimed.2008.02.009 | ||||
16. Birkenfeld S, Belfer RG, Chared M, et al. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test. J Med Screen 2011; 18:135-41. http://dx.doi.org/10.1258/jms.2011.010147 | ||||
17. Ciatto S, Martinelli F, Castiglione G, et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007; 96:218-21. http://dx.doi.org/10.1038/sj.bjc.6603534 | ||||
18. Castiglione G, Grazzini G, Ciatto S. Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening. Br J Cancer 1992; 65:942-4. http://dx.doi.org/10.1038/bjc.1992.197 PMid:1616868 PMCid:1977762 | ||||
19. Castiglione G, Sala P, Ciatto S, et al. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev 1994; 3:399-405. http://dx.doi.org/10.1097/00008469-199409000-00003 | ||||
20. Denis B, Ruetsch M, Strentz P, et al. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 2007; 56:1579-84. http://dx.doi.org/10.1136/gut.2007.126037 | ||||
21. Guittet L, Bouvier V, Mariotte N, et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009; 125:1127-33. http://dx.doi.org/10.1002/ijc.24407 | ||||
22. Do C, Bertrand C, Palasse J, et al. A new biomarker that predicts colonic neoplasia outcome in patients with hyperplastic colonic polyps. Cancer Prev Res (Phila) 2012; 5:675-84. http://dx.doi.org/10.1158/1940-6207.CAPR-11-0408 |